Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection

American Journal of Medicine

Volumn 105, Issue 1 A, 1998, Pages 27S-31S

  Parmley, William W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; ISOSORBIDE DINITRATE; NITRIC OXIDE; RENIN;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR AUTOREGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; ENZYME INHIBITION; HEART DEATH; HEART FAILURE; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0032490702     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(98)00208-3     Document Type: Conference Paper

References (20)

1. Punzi H.A., Zusman R.M. Captopril. Messerli F.H. Cardiovascular Drug Therapy. 2nd ed. 1996;726-742 WB Saunders, Philadelphia.
2. Brunner H.R., Waeber B., Nussberger J. Angiotensin-converting enzyme inhibitors. Messerli F.H. Cardiovascular Drug Therapy. 2nd ed. 1996;690-711 WB Saunders, Philadelphia.
3. Carretero O.A., Scicli A.G. The renal kallikrein-kinin system. Am J Physiol. 238:1980;F247-F255.
4. Ferguson R.K., Vlasses P.H., Rotmensch H.H. Clinical applications of angiotensin-converting enzyme inhibitors. Am J Med. 77:1984;690-698.
5. Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients a metaanalysis of 109 treatment studies . Am J Hypertens. 5:1992;95-110.
6. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
7. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med. 316:1987;1429-1435.
8. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure results of a Veterans Administration Cooperative Study . N Engl J Med. 314:1986;1547-1552.
9. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
10. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
11. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
12. Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the Survival and Ventricular Enlargement Trial . N Engl J Med. 327:1992;669-677.
13. St. John Sutton M. ACE-inhibition in the post-myocardial infarction patient. Messerli F.H. Cardiovascular Drug Therapy. 2nd ed. 1996;717-722 WB Saunders, Philadelphia.
14. Dzau V.J. Angiotensin-converting enzyme as a multimechanistic factor in CAD. J Myocard Ischemia. 7:(suppl 1):1995;6-14.
15. Chobanian A.V., Haudenschild C.C., Nickerson C., Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 15:1990;327-331.
16. Finta K.M., Fischer M.J., Lee L., et al. Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis. 100:1993;149-156.
17. Mancini G.B.J., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease the TREND (Trial on Reversing ENdothelial Dysfunction) study . Circulation. 94:1996;258-265.
18. Mancini G.B.J. Role of angiotensin-converting enzyme inhi-bition in reversal of endothelial dysfunction in coronary artery disease. Am J Med. 105:(suppl 1A):1998;40S-47S.
19. Weber M.A. Losartan. Messerli F.H. Cardiovascular Drug Therapy. 2nd ed. 1996;817-825 WB Saunders, Philadelphia.
20. de Gasparo M., Bottari S., Levens N.R. Characteristics of angiotensin II receptors and their role in cell and organ physiology. Laragh J.H., Brenner B.M. Hypertension Pathophysiology, Diagnosis, and Management . 2nd ed. 1995;1695-1720 Raven Press, New York.